Robert G Lambert Selected Research

Etanercept (Enbrel)

2/2024	Erosions on T1-Weighted Magnetic Resonance Imaging Versus Radiography of Sacroiliac Joints in Recent-Onset Axial Spondyloarthritis: 2-Year Data (EMBARK Trial and DESIR Cohort).
1/2021	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR.
1/2018	Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis.
1/2018	Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert G Lambert Research Topics

Disease

9	Axial Spondyloarthritis 02/2024 - 04/2014
6	Inflammation (Inflammations) 05/2024 - 01/2013
4	Non-Radiographic Axial Spondyloarthritis 09/2022 - 01/2018
3	Sacroiliitis 09/2022 - 01/2019
3	Ankylosing Spondylitis 01/2018 - 05/2002
3	Necrosis 01/2018 - 01/2013
2	Ankylosis 04/2014 - 01/2013
1	Spondylarthropathies 05/2024
1	Psoriatic Arthritis 01/2021
1	Rheumatoid Arthritis 01/2020
1	Nasopharyngitis 01/2018
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018
1	Metaplasia 04/2014
1	Infections 05/2002
1	Joint Diseases (Joint Disease) 05/2002

Drug/Important Bio-Agent (IBA)

4	Etanercept (Enbrel)FDA Link 02/2024 - 01/2018
4	Adalimumab (Humira)FDA Link 01/2018 - 01/2013
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 04/2014
2	FluoridesIBA 01/2019 - 01/2019
1	ixekizumabIBA 09/2022
1	C-Reactive ProteinIBA 09/2022
1	Interleukin-17 (Interleukin 17)IBA 09/2022
1	Antirheumatic Agents (DMARD)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Fenofibrate (CiL)FDA LinkGeneric 01/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2002
1	Neutralizing AntibodiesIBA 05/2002
1	Infliximab (Remicade)FDA Link 05/2002
1	GadoliniumIBA 05/2002

Therapy/Procedure

7	Therapeutics 01/2018 - 05/2002